Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy
Status:
Recruiting
Trial end date:
2041-04-30
Target enrollment:
Participant gender:
Summary
This clinical trial studies use of F-18 16 alpha-fluoroestradiol ([F-18] FES) positron
emission tomography (PET)/computed tomography (CT) in measuring tumor hormone receptor
expression in patients undergoing endocrine-targeted therapy for newly diagnosed breast
cancer or breast cancer that has come back or spread to other places in the body. Comparing
results of diagnostic procedures done before, during, and after hormone therapy may help
measure a patient's response to treatment.